I'm more optimistic, 113 is doing well for a larger market and moving into a pivotla Phase II study soon, I expect hold in trials lifted soon also, especially for GIST (drug of last resort).
Who knows? FDA may come to its senses, I can imagine the amount of complaints they are getiing from Drs, Patients, family and maybe even from the political arena will increase dramiatically after the EU stamp of approval of the drug for continued sales.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.